|
31/03/2020 |
News and press releases: Advancing regulatory science in the EU – new strategy adopted |
|
31/03/2020 |
Regulatory and procedural guideline: EMA Regulatory Science to 2025 - Strategic reflection
(new) |
|
31/03/2020 |
Overview of comments: Analysis and summaries of public consultation results: EMA Regulatory Science to 2025 - Strategic reflection
(new) |
|
31/03/2020 |
Regulatory science strategy (updated) |
|
31/03/2020 |
Management Board meeting: 19 March 2020
, European Medicines Agency, Amsterdam, the Netherlands, from 19/03/2020 to 19/03/2020 (updated) |
|
31/03/2020 |
Summary of opinion: Atectura Breezhaler, indacaterol, mometasone furoate, 26/03/2020, Positive |
|
31/03/2020 |
Summary of opinion: Bemrist Breezhaler, indacaterol, mometasone furoate, 26/03/2020, Positive |
|
31/03/2020 |
News and press releases: Update on treatments and vaccines against COVID-19 under development |
|
31/03/2020 |
Orphan designation: Autologous adult bone marrow-derived non-expanded CD133+ haematopoietic stem cells
for the: Treatment of Asherman's syndrome, 20/04/2017, Positive (updated) |
|
31/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), PM: decision on the application for modification of an agreed PIP, P/0384/2019 (updated) |
|
31/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Rubidium (82Rb) chloride, PM: decision on the application for modification of an agreed PIP, P/0391/2019 (updated) |
|
31/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Otezla, apremilast, PM: decision on the application for modification of an agreed PIP, P/0389/2019 (updated) |
|
31/03/2020 |
Other: Organisation chart: Human Medicines
(updated) |
|
31/03/2020 |
Human Medicines (updated) |
|
31/03/2020 |
PRAC recommendation on signal: PRAC recommendations on signals adopted at the 10-13 February 2020 PRAC meeting
(updated) |
|
31/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Chloroprocaine (hydrochloride), PM: decision on the application for modification of an agreed PIP, P/0382/2019 (updated) |
|
31/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Otezla, apremilast, PM: decision on the application for modification of an agreed PIP, P/0388/2019 (updated) |
|
31/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): 3-[5-[(1R,2S)-2-(2,2-difluoropropanoylamino)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)propoxy]indazol-1- yl]-N-[(3R)-tetrahydrofuran-3-yl]benzamide (AZD7594), P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0402/2019 |
|
31/03/2020 |
Human medicines European public assessment report (EPAR): Prasugrel Mylan, prasugrel besilate, Myocardial Infarction, Acute Coronary Syndrome, Angina, Unstable, 15/05/2018,  , 5, Authorised (updated) |
|
31/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Revestive, teduglutide, PM: decision on the application for modification of an agreed PIP, P/0410/2019 (updated) |
|
31/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Vitrakvi, Larotrectinib, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0401/2019 |
|
31/03/2020 |
Human medicines European public assessment report (EPAR): Grasustek, pegfilgrastim, Neutropenia, 20/06/2019,  ,  , 1, Authorised (updated) |
|
31/03/2020 |
Human medicines European public assessment report (EPAR): Flucelvax Tetra, Influenza virus surface antigens (haemagglutinin and neuraminidase)* , inactivated, of the following strains: A/xxxxx (H3N2)-like strain (reassortant used)/ A/xxxxx H1N1- like strain (reassortant used)/ B/xxxxx (Yamagata Lineage) – like strain (reassortant used)/ B/xxxxx (Victoria Lineage) – like strain (reassortant used), Influenza, Human, 12/12/2018, , 4, Authorised (updated) |
|
31/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (KTE-X19), W: decision granting a waiver in all age groups for all conditions/indications, P/0433/2019 |
|
31/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Bilastine, PM: decision on the application for modification of an agreed PIP, P/0408/2019 (updated) |
|
31/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Saxenda, liraglutide, PM: decision on the application for modification of an agreed PIP, P/0383/2019 (updated) |
|
31/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Xydalba, Dalbavancin, PM: decision on the application for modification of an agreed PIP, P/0377/2019 (updated) |
|
31/03/2020 |
Human medicines European public assessment report (EPAR): Atripla, efavirenz, emtricitabine, tenofovir disoproxil fumarate, HIV Infections, 13/12/2007, 33, Authorised (updated) |
|
31/03/2020 |
Human medicines European public assessment report (EPAR): Epclusa, Sofosbuvir, velpatasvir, Hepatitis C, Chronic, 06/07/2016,  , , 12, Authorised (updated) |
|
30/03/2020 |
Qualification of novel methodologies for medicine development (updated) |
|
30/03/2020 |
Human medicines European public assessment report (EPAR): Clopidogrel ratiopharm, clopidogrel hydrogen sulphate, Myocardial Infarction, Acute Coronary Syndrome, Peripheral Vascular Diseases, Stroke, 18/02/2015, , 9, Authorised (updated) |
|
30/03/2020 |
Veterinary medicines European public assessment report (EPAR): Purevax RCP, attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) / inactivated feline calicivirosis antigens (FCV 431 and G1 strains), attenuated feline panleucopenia virus (PLI IV), 23/02/2005, 13, Authorised (updated) |
|
30/03/2020 |
Veterinary medicines European public assessment report (EPAR): Purevax RCPCh, attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) / inactivated feline calicivirosis antigens (FCV 431 and G1 strains) / attenuated Chlamydophila felis (905 strain) / attenuated feline panleucopenia virus (PLI IV), 22/02/2005, 13, Authorised (updated) |
|
30/03/2020 |
Committee for Medicinal Products for Human Use (CHMP): 09-12 December 2019
, European Medicines Agency, Amsterdam, the Netherlands, from 09/12/2019 to 12/12/2019 (updated) |
|
30/03/2020 |
Withdrawn application: Rituximab Mabion, rituximab, Date of withdrawal: 16/03/2020, Initial authorisation |
|
30/03/2020 |
Withdrawn application: Rituximab Mabion, rituximab, Date of withdrawal: 16/03/2020, Initial authorisation |
|
30/03/2020 |
Veterinary medicines European public assessment report (EPAR): Zulvac 1 Bovis, inactivated bluetongue virus, serotype 1, 05/08/2011, , 7, Withdrawn (updated) |
|
30/03/2020 |
Minutes: CHMP ORGAM minutes for the meeting on 2 December 2019
(new) |
|
30/03/2020 |
Agenda: CHMP ORGAM agenda for the meeting on 2 December 2019
(new) |
|
30/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Sodium thiosulfate (STS), PM: decision on the application for modification of an agreed PIP, P/0368/2019 (updated) |
|
30/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Avacopan, RPM: decision refers to a refusal on the application for modification of an agreed PIP, P/0360/2019 (updated) |
|
30/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Pevonedistat, PM: decision on the application for modification of an agreed PIP, P/0386/2019 (updated) |
|
30/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): eflornithine (hydrochloride monohydrate),sulindac, RP: decision refers to a refusal on a proposed Paediatric Investigation Plan, P/0419/2019 |
|
30/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Influenza virus inactivated split virion (haemagglutinin and neuraminidase) of strain A (H1N1),Influenza virus inactivated split virion (haemagglutinin and neuraminidase) of strain A (H3N2),Influenza virus inactivated split virion (haemagglutinin and neuraminidase) of strain B (Victoria lineage),Influenza virus inactivated split virion (haemagglutinin and neuraminidase) of strain B (Yamagata lineage), P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0372/2019 (updated) |
|
30/03/2020 |
News and press releases: EMA to issue electronic certificates for medicines |
|
30/03/2020 |
Other: Information package for certificates of medicinal products issued by the European Medicines Agency
(updated) |
|
30/03/2020 |
Certification of medicinal products (updated) |
|
30/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Beclometasone dipropionate,formoterol fumarate dihydrate,glycopyrronium bromide (CHF 5993), PM: decision on the application for modification of an agreed PIP, P/0365/2019 (updated) |
|
30/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Xalkori, crizotinib, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0399/2019 |
|
30/03/2020 |
Committee meeting report: COMP meeting report on the review of applications for orphan designation: March 2020
(new) |
|
30/03/2020 |
Minutes: Minutes of the HMPC 23-25 September 2019 meeting
(new) |
|
30/03/2020 |
Human medicines European public assessment report (EPAR): Qtrilmet, metformin hydrochloride, Saxagliptin, dapagliflozin, Diabetes Mellitus, Type 2, 11/11/2019, 1, Authorised (updated) |
|
30/03/2020 |
Referral: Ulipristal acetate 5mg medicinal products
, Ulipristal acetate
, Article 31 referrals, Procedure started, 30/03/2020 (updated) |
|
30/03/2020 |
Veterinary medicines European public assessment report (EPAR): Purevax RCPCh FeLV, Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain), inactivated feline Calicivirosis antigens (FCV 431 and G1 strains), attenuated feline panleucopenia virus (PLI IV), FeLV recombinant canarypox virus (vCP97), 23/02/2005, 11, Authorised (updated) |
|
30/03/2020 |
Veterinary medicines European public assessment report (EPAR): Eurican Herpes 205, Canine herpesvirus (F205 strain) antigens, 26/03/2001, 10, Authorised (updated) |
|
30/03/2020 |
Veterinary medicines European public assessment report (EPAR): Purevax RCP FeLV, Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain), inactivated feline Calicivirosis antigens (FCV 431 and G1 strains), attenuated feline panleucopenia virus (PLI IV), FeLV recombinant canarypox virus (vCP97), 23/02/2005, 11, Authorised (updated) |
|
30/03/2020 |
Veterinary medicines European public assessment report (EPAR): Purevax FeLV, feline leukaemia virus recombinant canarypox virus (vCP97), 13/04/2000, 8, Authorised (updated) |
|
30/03/2020 |
Veterinary medicines European public assessment report (EPAR): Purevax RC, attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) / inactivated feline calicivirosis antigens (FCV 431 and G1 strains), 23/02/2005, 12, Authorised (updated) |
|
30/03/2020 |
Human medicines European public assessment report (EPAR): Tasigna, nilotinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 19/11/2007, 36, Authorised (updated) |
|
30/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Dupixent, dupilumab, PM: decision on the application for modification of an agreed PIP, P/0374/2019 (updated) |
|
30/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Prevymis, Letermovir, PM: decision on the application for modification of an agreed PIP, P/0362/2019 (updated) |
|
30/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Latuda, Lurasidone hydrochloride, PM: decision on the application for modification of an agreed PIP, P/0359/2019 (updated) |
|
30/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Daklinza, Daclatasvir, W: decision granting a waiver in all age groups for all conditions/indications, P/0367/2019 (updated) |
|
27/03/2020 |
Good clinical practice (updated) |
|
27/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Doptelet, Avatrombopag (maleate), PM: decision on the application for modification of an agreed PIP, P/0373/2019 (updated) |
|
27/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Plegridy, peginterferon beta-1a, PM: decision on the application for modification of an agreed PIP, P/0371/2019 (updated) |
|
27/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Volibris, ambrisentan, PM: decision on the application for modification of an agreed PIP, P/0370/2019 (updated) |
|
27/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Lubiprostone, PM: decision on the application for modification of an agreed PIP, P/0363/2019 (updated) |
|
27/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Selpercatinib, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0369/2019 |
|
27/03/2020 |
Referrals document: Nitrosamines EMEA-H-A5(3)-1490 - Questions and answers on 'Information on nitrosamines for marketing authorisation holders'
(updated) |
|
27/03/2020 |
Nitrosamine impurities (updated) |
|
27/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Remimazolam (as besylate), P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0364/2019 |
|
27/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Ganaxolone, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0361/2019 |
|
27/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Ilaris, Canakinumab, W: decision granting a waiver in all age groups for all conditions/indications, P/0366/2019 |
|
27/03/2020 |
News and press releases: EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic |
|
27/03/2020 |
Other: EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) substances
(updated) |
|
27/03/2020 |
Other: EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) routes of administration
(updated) |
|
27/03/2020 |
Other: EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) pharmaceutical dose forms
(updated) |
|
27/03/2020 |
Other: EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) organisations
(updated) |
|
27/03/2020 |
Regulatory and procedural guideline: EudraVigilance registration manual
(updated) |
|
27/03/2020 |
EudraVigilance: how to register (updated) |
|
27/03/2020 |
Other: Vendor registration in the EudraVigilance external compliance testing environment (XCOMP) - Registration procedure
(updated) |
|
27/03/2020 |
News and press releases: No change to product information for breast cancer medicine Tyverb following re-assessment of data |
|
27/03/2020 |
News and press releases: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020 |
|
27/03/2020 |
Summary of opinion: Zolgensma, onasemnogene abeparvovec, 26/03/2020, Positive |
|
27/03/2020 |
Summary of opinion: Intelence, etravirine, 26/03/2020, Positive |
|
27/03/2020 |
Summary of opinion: Zeposia, ozanimod, 26/03/2020, Positive |
|
27/03/2020 |
Summary of opinion: Jorveza, budesonide, 26/03/2020, Positive |
|
27/03/2020 |
Committee meeting report: HMPC meeting report on European Union herbal monographs, guidelines and other activities - 2-4 March 2020
(new) |
|
27/03/2020 |
Other: HMPC: overview of assessment work - priority list
(updated) |
|
27/03/2020 |
Summary of opinion: Fluad Tetra, influenza vaccine (surface antigen, inactivated, adjuvanted), 26/03/2020, Positive |
|
27/03/2020 |
Summary of opinion: Ruconest, conestat alfa, 26/03/2020, Positive |
|
27/03/2020 |
Minutes: Minutes of the COMP meeting 3-5 December 2019
(new) |
|
27/03/2020 |
Withdrawn application: Doxorubicin Hydrochloride Tillomed, doxorubicin, Date of withdrawal: 02/03/2020, Initial authorisation |
|
27/03/2020 |
News and press releases: Restrictions in use of cyproterone due to meningioma risk |
|
27/03/2020 |
Summary of opinion: Cosentyx, secukinumab, 26/03/2020, Positive |
|
27/03/2020 |
Summary of opinion: Sarclisa, isatuximab, 26/03/2020, Positive |
|
27/03/2020 |
Summary of opinion: Nepexto, etanercept, 26/03/2020, Positive |
|
27/03/2020 |
Summary of opinion: Kineret, anakinra, 26/03/2020, Positive |
|
27/03/2020 |
News and press releases: Recommendations to restrict use of fosfomycin antibiotics |
|
27/03/2020 |
Summary of opinion: Adcetris, brentuximab vedotin, 26/03/2020, Positive |
|
27/03/2020 |
Annex to CHMP highlights: Scientific advice and protocol assistance adopted during the CHMP meeting 9-12 March 2020
(new) |
|
27/03/2020 |
Referral: Budesonide SUN
, budesonide
, Article 29(4) referrals, Opinion provided by Committee for Medicinal Products for Human Use, 26/03/2020 |
|
27/03/2020 |
News and press releases: No change is needed in use of direct oral anticoagulants following EMA-funded study |
|
27/03/2020 |
Referral: Fosfomycin-containing medicinal products
, fosfomycin calcium, fosfomycin disodium, fosfomycin sodium, fosfomycin
trometamol
, Afastural,Berny Adulti,Danifos Adulti,Fomicyt,Fosfocin,Fosfocina,Fosfocine,Fosfopharm,Fosfuro,Fosmol,Fostrofemge,Gynofostrome,Infectofos,Infeur Adulti,Interfos,Monural,Monuril,Monurol,Rapidnorm,Solufos,Symural,Uridoz,Urifos,Urinex,Urofast,Uromaste,Uroseptic, Article 31 referrals, Opinion provided by Committee for Medicinal Products for Human Use, 26/03/2020, 27/03/2020 (updated) |
|
27/03/2020 |
Referral: Methocarbamol / paracetamol-containing medicinal products
, methocarbamol/paracetamol
, Robaxisal compuesto, Article 31 referrals, Opinion provided by Committee for Medicinal Products for Human Use, 26/03/2020, 27/03/2020 (updated) |
|
27/03/2020 |
Report: Medicinal products for human use: monthly figures - February 2020
(new) |
|
27/03/2020 |
Human medicines European public assessment report (EPAR): Caelyx pegylated liposomal, doxorubicin hydrochloride, Sarcoma, Kaposi, Multiple Myeloma, Ovarian Neoplasms, Breast Neoplasms, 20/06/1996, 31, Authorised (updated) |
|
27/03/2020 |
Human medicines European public assessment report (EPAR): Kaletra, lopinavir, ritonavir, HIV Infections, 19/03/2001, 53, Authorised (updated) |
|
27/03/2020 |
News and press releases: Benefits of medicines containing combination of methocarbamol and paracetamol continue to outweigh risks |
|
27/03/2020 |
Human medicines European public assessment report (EPAR): Briviact (in Italy: Nubriveo), Brivaracetam, Epilepsy, 13/01/2016, , 8, Authorised (updated) |
|
27/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Onasemnogenum abeparvovecum, PM: decision on the application for modification of an agreed PIP, P/0315/2019 (updated) |
|
27/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Pretomanid, PM: decision on the application for modification of an agreed PIP, P/0337/2019 (updated) |
|
27/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Risdiplam (RO7034067), PM: decision on the application for modification of an agreed PIP, P/0349/2019 (updated) |
|
27/03/2020 |
Summary of opinion: Pretomanid FGK, pretomanid, 26/03/2020, Positive |
|
27/03/2020 |
Veterinary medicines European public assessment report (EPAR): Aftovaxpur DOE, Maximum three of the following purified, inactivated foot-and-mouth disease virus strains: O1 Manisa ≥ 6 PD50*; O1 BFS ≥ 6 PD50*; O Taiwan 3/97 ≥ 6 PD50*; A22 Iraq ≥ 6 PD50*; A24 Cruzeiro ≥ 6 PD50*; A Turkey 14/98 ≥ 6 PD50*; Asia 1 Shamir ≥ 6 PD50*; SAT2 Saudi Arabia ≥ 6 PD50*; * PD50 – 50% protective dose in cattle as described in Ph. Eur. monograph 0063., 15/07/2013, 16/05/2013, 8, Authorised (updated) |
|
27/03/2020 |
Veterinary medicines European public assessment report (EPAR): BTVPUR, bluetongue-virus serotype-1 antigen / bluetongue-virus serotype-8 antigen , 17/12/2010, 10, Authorised (updated) |
|
27/03/2020 |
Human medicines European public assessment report (EPAR): Veyvondi, vonicog alfa, von Willebrand Diseases, 31/08/2018, , 1, Authorised (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Odevixibat, PM: decision on the application for modification of an agreed PIP, P/0316/2019 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Influenza virus surface antigens (haemagglutinin) of strain A (H1N1),influenza virus surface antigens (haemagglutinin) of strain A (H3N2),influenza virus surface antigens (haemagglutinin) of strain B (Victoria lineage),influenza virus surface antigens (haemagglutinin) of strain B (Yamagata lineage), W: decision granting a waiver in all age groups for all conditions/indications, P/0340/2019 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Larotrectinib, PM: decision on the application for modification of an agreed PIP, P/0318/2019 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Dovato, lamivudine,dolutegravir, PM: decision on the application for modification of an agreed PIP, P/0319/2019 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): 2-hydroxypropyl-ß-cyclodextrin (HP-ß-CD), PM: decision on the application for modification of an agreed PIP, P/0348/2019 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Liquid ethanolic extract 30 per cent (w/w) of Allium cepa L. (fresh bulb) and Citrus limon (L.) Burm. f. (fresh fruit),Paullinia cupana Kunth,Theobroma cacao L., PM: decision on the application for modification of an agreed PIP, P/0321/2019 (updated) |
|
26/03/2020 |
Human medicines European public assessment report (EPAR): Prevenar 13, pneumococcal polysaccharide serotype 1 / pneumococcal polysaccharide serotype 14 / pneumococcal polysaccharide serotype 18C / pneumococcal polysaccharide serotype 19A, pneumococcal polysaccharide serotype 19F / pneumococcal polysaccharide serotype 23F / pneumococcal polysaccharide serotype 3 / pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6A, pneumococcal polysaccharide serotype 6B / pneumococcal polysaccharide serotype 7F / pneumococcal polysaccharide serotype 9V protein, Pneumococcal Infections, Immunization, 09/12/2009, 37, Authorised (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Anti-respiratory syncytial virus human IgG1κ monoclonal antibody (MEDI8897), P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0305/2019 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Upadacitinib, PM: decision on the application for modification of an agreed PIP, P/0322/2019 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Kymriah, tisagenlecleucel, PM: decision on the application for modification of an agreed PIP, P/0323/2019 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Finerenone, PM: decision on the application for modification of an agreed PIP, P/0324/2019 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Ozempic, semaglutide, PM: decision on the application for modification of an agreed PIP, P/0326/2019 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Etrolizumab, PM: decision on the application for modification of an agreed PIP, P/0327/2019 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Cotellic, Cobimetinib, PM: decision on the application for modification of an agreed PIP, P/0306/2019 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Fevipiprant, PM: decision on the application for modification of an agreed PIP, P/0341/2019 (updated) |
|
26/03/2020 |
Orphan designation: 2-Chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide (namodenoson)
for the: Treatment of hepatocellular carcinoma, 09/10/2015, Positive (updated) |
|
26/03/2020 |
Orphan designation: Osilodrostat
for the: Treatment of Cushing's syndrome, 15/10/2014, Positive (updated) |
|
26/03/2020 |
Human medicines European public assessment report (EPAR): Lysodren, Mitotane, Adrenal Cortex Neoplasms, 28/04/2004, 15, Authorised (updated) |
|
26/03/2020 |
Human medicines European public assessment report (EPAR): Gazyvaro, Obinutuzumab, Leukemia, Lymphocytic, Chronic, B-Cell, 22/07/2014,  , , 9, Authorised (updated) |
|
26/03/2020 |
Orphan designation: Human monoclonal IgG2 antibody against tissue factor pathway inhibitor
for the: Treatment of haemophilia A, 22/02/2018, Withdrawn (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Dermatophagoides pteronyssinus,dermatophagoides farinae allergen extract, PM: decision on the application for modification of an agreed PIP, P/0328/2019 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Afstyla, lonoctocog alfa, PM: decision on the application for modification of an agreed PIP, P/0329/2019 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Cinqaero, Reslizumab, PM: decision on the application for modification of an agreed PIP, P/0284/2019 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Feraccru, ferric maltol, PM: decision on the application for modification of an agreed PIP, P/0330/2019 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Evarrest, human fibrinogen,human thrombin, PM: decision on the application for modification of an agreed PIP, P/0339/2019 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Cometriq, cabozantinib, PM: decision on the application for modification of an agreed PIP, P/0331/2019 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Jardiance, empagliflozin, PM: decision on the application for modification of an agreed PIP, P/0345/2019 (updated) |
|
26/03/2020 |
Human medicines European public assessment report (EPAR): Advate, octocog alfa, Hemophilia A, 02/03/2004, 25, Authorised (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Votrient, pazopanib, PM: decision on the application for modification of an agreed PIP, P/0333/2019 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Betmiga, Mirabegron, RPM: decision refers to a refusal on the application for modification of an agreed PIP, P/0350/2017 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Entresto, sacubitril,valsartan, PM: decision on the application for modification of an agreed PIP, P/0344/2019 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Bexsero, recombinant Neisseria meningitidis group B NHBA fusion protein,recombinant Neisseria meningitidis group B NadA protein,recombinant Neisseria meningitidis group B fHbp fusion protein,Outer Membrane Vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 measured as amount of total protein containing the PorA P1.4, PM: decision on the application for modification of an agreed PIP, P/0334/2019 (updated) |
|
26/03/2020 |
International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Translarna, Ataluren, PM: decision on the application for modification of an agreed PIP, P/0335/2019 (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): neisseria meningitidis serogroup A polysaccharide conjugated to tetanus toxoid / N. meningitidis,serogroup C polysaccharide conjugated to tetanus toxoid / N. meningitidis serogroup Y polysaccharide,conjugated to tetanus toxoid / N. meningitidis serogroup W polysaccharide conjugated to tetanus,toxoid (MenACYW), PM: decision on the application for modification of an agreed PIP, P/0169/2019 (updated) |
|
26/03/2020 |
Human medicines European public assessment report (EPAR): Dovato, dolutegravir sodium, lamivudine, HIV Infections, 01/07/2019, , 1, Authorised (updated) |
|
26/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Januvia, sitagliptin, PM: decision on the application for modification of an agreed PIP, P/0358/2019 (updated) |
|
26/03/2020 |
Human medicines European public assessment report (EPAR): Sifrol, pramipexole dihydrochloride monohydrate, Restless Legs Syndrome, Parkinson Disease, 13/10/1997, 33, Authorised (updated) |
|
26/03/2020 |
Committee meeting report: PDCO monthly report of opinions on paediatric investigation plans and other activities 25-28 February 2020
(new) |
|
25/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): 2-(3-(1-carboxy-5-[(6-[18F]fluoropyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid, W: decision granting a waiver in all age groups for all conditions/indications, P/0357/2019 |
|
25/03/2020 |
International Coalition of Medicines Regulatory Authorities (ICMRA) (updated) |
|
25/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Autologous human T cells genetically modified ex-vivo with a lentiviral vector encoding a chimeric antigen receptor (CAR) for B-cell maturation antigen (BCMA) (JNJ-68284528), W: decision granting a waiver in all age groups for all conditions/indications, P/0353/2019 |
|
25/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Ecopipam (hydrochloride), P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0351/2019 |
|
25/03/2020 |
Periodic safety update single assessment: Fosfomycin (IV formulation): List of nationally authorised medicinal products - PSUSA/00010336/201907
(new) |
|
25/03/2020 |
Human medicines European public assessment report (EPAR): Pazenir, paclitaxel, Breast Neoplasms, 06/05/2019, , 4, Authorised (updated) |
|
25/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Botulinum toxin type A, W: decision granting a waiver in all age groups for all conditions/indications, P/0307/2019 |
|
25/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): 7-(2-Methoxy-3,5-dimethylpyridin-4-yl)-1-[(3S)-tetrahydrofuran-3-yl]-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one maleate, W: decision granting a waiver in all age groups for all conditions/indications, P/0354/2019 |
|
25/03/2020 |
Implications of coronavirus disease (COVID-19) on methodological aspects of ongoing clinical trials |
|
25/03/2020 |
Scientific guideline: Points to consider on implications of Coronavirus disease (COVID-19) on methodological aspects of ongoing clinical trials
(new) |
|
25/03/2020 |
Biostatistics (updated) |
|
25/03/2020 |
Agenda: Agenda - PDCO agenda of the 24-27 March 2020 meeting
(new) |
|
25/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): aprocitentan, W: decision granting a waiver in all age groups for all conditions/indications, P/0356/2019 |
|
25/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Infigratinib, W: decision granting a waiver in all age groups for all conditions/indications, P/0301/2019 |
|
25/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Fexapotide (friflutate), W: decision granting a waiver in all age groups for all conditions/indications, P/0346/2019 |
|
25/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Zofenopril / nebivolol, W: decision granting a waiver in all age groups for all conditions/indications, P/0308/2019 |
|
25/03/2020 |
Clinical trials in human medicines (updated) |
|
25/03/2020 |
Human medicines European public assessment report (EPAR): MabThera, rituximab, Lymphoma, Non-Hodgkin, Arthritis, Rheumatoid, Leukemia, Lymphocytic, Chronic, B-Cell, 02/06/1998, 50, Authorised (updated) |
|
25/03/2020 |
Human medicines European public assessment report (EPAR): Lojuxta, Lomitapide, Hypercholesterolemia, 31/07/2013, ,  , 12, Authorised (updated) |
|
25/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Atropine (sulphate) / Obidoxime (chloride), W: decision granting a waiver in all age groups for all conditions/indications, P/0309/2019 |
|
25/03/2020 |
Human medicines European public assessment report (EPAR): Prevymis, Letermovir, Cytomegalovirus Infections, 08/01/2018, , , 6, Authorised (updated) |
|
25/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): human fibrinogen, W: decision granting a waiver in all age groups for all conditions/indications, P/0352/2019 |
|
25/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): rosuvastatin / ramipril, W: decision granting a waiver in all age groups for all conditions/indications, P/0343/2019 |
|
25/03/2020 |
Human medicines European public assessment report (EPAR): Qtern, Saxagliptin, dapagliflozin propanediol monohydrate, Diabetes Mellitus, Type 2, 15/07/2016, 5, Authorised (updated) |
|
25/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): levonorgestrel, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0302/2019 |
|
25/03/2020 |
Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Angioedemas, Hereditary, 22/11/2018, , , , 2, Authorised (updated) |
|
25/03/2020 |
Report: 10-year annual report on MUMS/limited market scheme for veterinary medicines
(new) |
|
25/03/2020 |
News and press releases: Ten years of MUMS: 22 new veterinary medicines authorised for minor uses and minor species |
|
25/03/2020 |
Requesting a minor use / minor species (MUMS) / limited market classification |
|
25/03/2020 |
Minor use / minor species and limited markets (updated) |
|
25/03/2020 |
Human medicines European public assessment report (EPAR): Mysimba, bupropion hydrochloride, naltrexone hydrochloride, Obesity, Overweight, 26/03/2015, , 15, Authorised (updated) |
|
25/03/2020 |
List of medicines under additional monitoring (updated) |
|
25/03/2020 |
Medicines under additional monitoring: List of medicinal products under additional monitoring
(updated) |
|
25/03/2020 |
Medicines under additional monitoring: List of medicinal products under additional monitoring
(updated) |
|
25/03/2020 |
EudraVigilance (updated) |
|
25/03/2020 |
Other: EudraVigilance Operational Plan - Milestones 2020 to 2022
(new) |
|
25/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): belantamab mafodotin, W: decision granting a waiver in all age groups for all conditions/indications, P/0347/2019 |
|
25/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): dostarlimab, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0303/2019 |
|
25/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): PEGylated-fibroblast growth factor 21 (BMS-986036), P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0336/2019 |
|
25/03/2020 |
Human medicines European public assessment report (EPAR): Karvea, irbesartan, Hypertension, 26/08/1997, 38, Authorised (updated) |
|
25/03/2020 |
Human medicines European public assessment report (EPAR): Mirapexin, pramipexole dihydrochloride monohydrate, Restless Legs Syndrome, Parkinson Disease, 23/02/1998, 36, Authorised (updated) |
|
25/03/2020 |
Human medicines European public assessment report (EPAR): Ameluz, 5-aminolevulinic acid hydrochloride, Keratosis, Actinic, Carcinoma, Basal Cell, 13/12/2011, 15, Authorised (updated) |
|
25/03/2020 |
Public Statement: Public statement on Kromeya: Withdrawal of the marketing authorisation in the European Union
(new) |
|
25/03/2020 |
Periodic safety update single assessment: Fosfomycin (oral formulation): List of nationally authorised medicinal products - PSUSA/00010326/201907
(new) |
|
25/03/2020 |
Human medicines European public assessment report (EPAR): Kromeya, adalimumab, Arthritis, Rheumatoid, Arthritis, Juvenile Rheumatoid, Psoriasis, Arthritis, Psoriatic, Spondylitis, Ankylosing, Uveitis, Colitis, Ulcerative, Crohn Disease, 02/04/2019, , , 4, Withdrawn (updated) |
|
25/03/2020 |
Human medicines European public assessment report (EPAR): Zalasta, olanzapine, Schizophrenia, Bipolar Disorder, 27/09/2007, , 17, Authorised (updated) |
|
25/03/2020 |
Human medicines European public assessment report (EPAR): Vaxelis, Diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens: pertussis toxoid, filamentous haemagglutinin, pertactin, fimbriae Types 2 and 3, hepatitis B surface antigen produced in yeast cells, poliovirus (inactivated): type 1 (Mahoney), type 2 (MEF-1), type 3 (Saukett) produced in Vero cells/ Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to meningococcal protein., Meningitis, Haemophilus, Poliomyelitis, Tetanus, Diphtheria, Whooping Cough, Hepatitis B, 15/02/2016, , 7, Authorised (updated) |
|
25/03/2020 |
Veterinary medicines European public assessment report (EPAR): Credelio, lotilaner, 23/04/2017, 4, Authorised (updated) |
|
25/03/2020 |
Human medicines European public assessment report (EPAR): Fasturtec, rasburicase, Hyperuricemia, 23/02/2001, 25, Authorised (updated) |
|
25/03/2020 |
Human medicines European public assessment report (EPAR): Xeristar, duloxetine, Anxiety Disorders, Depressive Disorder, Major, Diabetic Neuropathies, 17/12/2004, 29, Authorised (updated) |
|
25/03/2020 |
Human medicines European public assessment report (EPAR): Ecalta, anidulafungin, Candidiasis, 20/09/2007, 21, Authorised (updated) |
|
24/03/2020 |
Human medicines European public assessment report (EPAR): Mayzent, Siponimod fumaric acid, Multiple Sclerosis, Relapsing-Remitting, 13/01/2020, , 1, Authorised (updated) |
|
24/03/2020 |
Human medicines European public assessment report (EPAR): Cuprymina, copper (64Cu) chloride, Radionuclide Imaging, 23/08/2012, 7, Authorised (updated) |
|
24/03/2020 |
News and press releases: Global regulators map out data requirements for phase 1 COVID-19 vaccine trials |
|
24/03/2020 |
Human medicines European public assessment report (EPAR): Xgeva, denosumab, Fractures, Bone, Neoplasm Metastasis, 13/07/2011, 19, Authorised (updated) |
|
24/03/2020 |
Human medicines European public assessment report (EPAR): Kisqali, ribociclib succinate, Breast Neoplasms, 22/08/2017, , 3, Authorised (updated) |
|
24/03/2020 |
Human medicines European public assessment report (EPAR): Rezolsta, darunavir, cobicistat, HIV Infections, 19/11/2014, 10, Authorised (updated) |
|
24/03/2020 |
Human medicines European public assessment report (EPAR): Rotarix, human rotavirus, live attenuated, Immunization, Rotavirus Infections, 21/02/2006, 35, Authorised (updated) |
|
24/03/2020 |
News and press releases: COVID-19: Beware of falsified medicines from unregistered websites |
|
24/03/2020 |
Buying medicines online (updated) |
|
24/03/2020 |
Human medicines European public assessment report (EPAR): Suliqua, insulin glargine, lixisenatide, Diabetes Mellitus, Type 2, 11/01/2017, , 5, Authorised (updated) |
|
24/03/2020 |
Human medicines European public assessment report (EPAR): Biktarvy, bictegravir, emtricitabine, tenofovir alafenamide, fumarate, HIV Infections, 21/06/2018, , 5, Authorised (updated) |
|
24/03/2020 |
Paediatric investigation plans: questions and answers (updated) |
|
24/03/2020 |
Regulatory and procedural guideline: Guidance on paediatric submissions
(new) |
|
24/03/2020 |
Human medicines European public assessment report (EPAR): Levetiracetam Actavis, levetiracetam, Epilepsy, 03/10/2011, , 15, Authorised (updated) |
|
24/03/2020 |
Human medicines European public assessment report (EPAR): Truvada, emtricitabine, tenofovir disoproxil fumarate, HIV Infections, 20/02/2005, 41, Authorised (updated) |
|
24/03/2020 |
Human medicines European public assessment report (EPAR): Aripiprazole Accord, aripiprazole, Schizophrenia, Bipolar Disorder, 15/11/2015, , 9, Authorised (updated) |
|
24/03/2020 |
Human medicines European public assessment report (EPAR): Privigen, human normal immunoglobulin (IVIg), Purpura, Thrombocytopenic, Idiopathic, Bone Marrow Transplantation, Immunologic Deficiency Syndromes, Guillain-Barre Syndrome, Mucocutaneous Lymph Node Syndrome, 24/04/2008, 25, Authorised (updated) |
|
24/03/2020 |
Human medicines European public assessment report (EPAR): Trazimera, trastuzumab, Stomach Neoplasms, Breast Neoplasms, 26/07/2018, , , 5, Authorised (updated) |
|
24/03/2020 |
Human medicines European public assessment report (EPAR): Karvezide, irbesartan, hydrochlorothiazide, Hypertension, 16/10/1998, 37, Authorised (updated) |
|
24/03/2020 |
Human medicines European public assessment report (EPAR): Insulin lispro Sanofi, insulin lispro, Diabetes Mellitus, 18/07/2017, , , 5, Authorised (updated) |
|
24/03/2020 |
Human medicines European public assessment report (EPAR): DuoResp Spiromax, budesonide, formoterol fumarate dihydrate, Pulmonary Disease, Chronic Obstructive, Asthma, 28/04/2014, 9, Authorised (updated) |
|
24/03/2020 |
Human medicines European public assessment report (EPAR): BiResp Spiromax, budesonide, formoterol fumarate dihydrate, Pulmonary Disease, Chronic Obstructive, Asthma, 28/04/2014, 9, Authorised (updated) |
|
24/03/2020 |
Human medicines European public assessment report (EPAR): Votrient, pazopanib, Carcinoma, Renal Cell, 14/06/2010, 23, Authorised (updated) |
|
23/03/2020 |
Veterinary medicines European public assessment report (EPAR): Comfortis, spinosad, 11/02/2011, 7, Authorised (updated) |
|
23/03/2020 |
Human medicines European public assessment report (EPAR): Zypadhera, olanzapine pamoate, Schizophrenia, 19/11/2008, 19, Authorised (updated) |
|
23/03/2020 |
Direct healthcare professional communication (DHPC): Ulipristal acetate 5 mg for uterine fibroids not to be used during ongoing review of liver injury risk, Active substance: uliprista acetate 5mg, DHPC type: Interim measures, Last updated: 23/03/2020 |
|
23/03/2020 |
Human medicines European public assessment report (EPAR): Cubicin, daptomycin, Gram-Positive Bacterial Infections, Bacteremia, Soft Tissue Infections, Endocarditis, Bacterial, 19/01/2006, 32, Authorised (updated) |
|
23/03/2020 |
Human medicines European public assessment report (EPAR): Gardasil, human papillomavirus type 6 L1 protein, human papillomavirus type 11 L1 protein, human papillomavirus type 16 L1 protein, human papillomavirus type 18 L1 protein, Papillomavirus Infections, Uterine Cervical Dysplasia, Condylomata Acuminata, Immunization, 20/09/2006, 42, Authorised (updated) |
|
23/03/2020 |
Direct healthcare professional communication: Ulipristal acetate 5 mg for uterine fibroids not to be used during ongoing review of liver injury risk
(new) |
|
23/03/2020 |
Paediatric Committee (PDCO): 12-15 November 2019
, European Medicines Agency, Amsterdam, The Netherlands, from 12/11/2019 to 15/11/2019 (updated) |
|
23/03/2020 |
Minutes: Minutes - PDCO minutes of the 12-15 November 2019 meeting
(new) |
|
23/03/2020 |
Agenda: Agenda - CHMP agenda of the 23-26 March 2020 meeting
(new) |
|
23/03/2020 |
Human medicines European public assessment report (EPAR): Trogarzo, Ibalizumab, HIV Infections, 26/09/2019, , 1, Authorised (updated) |
|
23/03/2020 |
Human medicines European public assessment report (EPAR): Atriance, nelarabine, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, 22/08/2007, , , 23, Authorised (updated) |
|
23/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Equine immunoglobulin F(ab')2 fragments targeting Shiga toxin, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0304/2019 |
|
23/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Baloxavir marboxil, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0300/2019 |
|
23/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): recombinant adeno-associated viral vector serotype 2 carrying the gene for the human aromatic L-amino acid decarboxylase protein, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0310/2019 |
|
23/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Tirzepatide, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0311/2019 |
|
23/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): liposomal ciclosporin A (L-CsA), P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0312/2019 |
|
23/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Zejula, Niraparib (tosylate monohydrate), P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0313/2019 |
|
23/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Eptinezumab, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0314/2019 |
|
23/03/2020 |
Opinion/decision on a Paediatric investigation plan (PIP): Recombinant Hepatitis B vaccine, RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s), P/0342/2019 |
